摘要
目的研究结直肠癌肝脏转移微小RNA(microRNA,miRNA)表达的差异以及相关特性。方法收集2009年4月至2010年11月期间首都医科大学附属复兴医院的10例伴或不伴肝脏转移的结直肠癌患者的肿瘤组织标本,应用miRNA芯片方法对2组样本的miRNA表达差异情况进行研究,并通过实时定量PCR对miRNA的芯片表达差异进行验证。结果芯片结果筛选出6种结直肠癌肝脏转移组较非转移组表达失调的miRNA(上调的miR-224、miR-1236和miR-622,下调的miR-155、miR-342-5p和miR-363),选取显著上调(即差异信号值大于500)的miR-224进行实时定量PCR验证,结果与芯片实验结果相一致。结论 miR-224可能通过调节其靶基因而在结直肠癌肝脏转移中起重要作用,miR-224可能成为未来结直肠癌生物标记或治疗方法的一个研究方向。
Objective To explore the microRNA(miRNA) expression changes and related miRNA characteristics of colorectal cancer(CRC) with hepatic metastasis by miRNA microarray.Methods The fresh specimens of primary CRC were collected in 10 patients during operation,which with hepatic metastasis or not.miRNA microarray analysis was performed to compare the miRNA expression levels in two groups.The different expression levels of miRNA were validated by quantitative real-time PCR analysis.Results A total of six dysregulated miRNAs were identified in the CRC patients with hepatic metastasis comparing with CRC patients without hepatic metastasis,including 3 up-regulated miRNAs(miR-224,miR-1236,and miR-622) and 3 down-regulated miRNAs(miR-155,miR-342-5p,and miR-363),and the quantitative real-time PCR result of miR-224 consisted with the microarray finding.Conclusions miR-224 may be involved in the process of CRC with hepatic metastasis pathogenesis.miR-224 would be a research direction on a new biomarker or therapic method in CRC with hepatic metastasis.
出处
《中国普外基础与临床杂志》
CAS
2013年第5期499-502,共4页
Chinese Journal of Bases and Clinics In General Surgery
基金
北京市教育委员会科技发展计划面上项目(项目编号:KM200910025022)~~